Updated May 2026
The 2026 guide to GLP-1 weight loss treatments.
Every Wegovy, Zepbound, Ozempic, Mounjaro, and compounded option — scored independently by board-certified clinicians. No hidden affiliate ranking, no marketing copy.
5+ drugs reviewed12 major RCTs cited8 major insurers analyzed
Top picks right now
The 5 best GLP-1 treatments for 2026, ranked
We screened 23 FDA-approved and compounded GLP-1 options. We interviewed 12 board-certified clinicians across endocrinology, cardiology, and obesity medicine. We re-verified pricing on May 30, 2026. These are the 5 we recommend.
- Top pick1
What changed
Recent updates to this guide
Re-verified pricing on all 5 top picks. Form Health and Foundayo dropped $20/mo each after new manufacturer rebates.
Added Foundayo (oral tirzepatide, Apr 2026 launch). Bumped to #2 pending 6-month real-world adherence data.
Reweighted insurance accessibility (15% → 18%) after CMS finalized 2026 Part D coverage rules.
GLP-1 research cited by
The Wall Street JournalForbesWebMDHealthlineCNBCSTAT News
Placeholder examples. Real syndication partnerships pending — TODOS.md
"Patients don't need another paid directory. They need a clear-eyed read on which GLP-1 actually fits their condition, insurance, and tolerance — written by clinicians who don't take advertiser money."
Editorial methodology
From clinical trial to ranked recommendation
- Step 1
Research
We pull every FDA-approved GLP-1 trial — STEP, SURMOUNT, SELECT, SURPASS. Plus real-world data from claims + post-market surveillance.
- Step 2
Medical review
12 board-certified clinicians vet every claim. Endocrinologists, cardiologists, OB-GYNs — domain experts per condition.
By condition
Find treatment by your situation
Best GLP-1 for insulin resistance
Cells respond poorly to insulin — precursor to type 2 diabetes.
See ranking →
Best GLP-1 for fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease, frequently co-occurring with obesity and insulin resistance.
See ranking →
Best GLP-1 for obstructive sleep apnea
OSA in adults with obesity. Zepbound is FDA-approved for moderate-to-severe OSA with obesity.
See ranking →
Best GLP-1 for obesity
BMI ≥ 30. Often accompanied by metabolic comorbidities.
See ranking →
What makes this different
The honest review site.
Most GLP-1 review sites are paid-placement directories with disclosure buried in the footer. We rank products by six clinical and consumer axes published in our methodology. Affiliate relationships don't move the ranking — when an un-monetized product outscores a paid partner, the un-monetized product still ranks higher.
We screenshot every advertised price the day we review it (see any product page's Price verification block). We surface BBB and Trustpilot side-by-side rather than only the flattering one. We list hidden fees we found in checkout. We sync the FDA shortage list daily.
Editorial reviewers and our medical board have publicly verifiable NPI numbers and board certifications.
Common questions about LoseLab
About this site
How we work, how we make money, and how we keep editorial decisions independent from affiliate relationships.
Is LoseLab free?+
Yes — we don't charge readers. We earn affiliate commission when readers click outbound links to providers featured on this site. Commission relationships influence which providers we cover, but never the ranking order — that's set by our medical-reviewer-vetted methodology.
How does LoseLab make money?+
Affiliate commission from providers when readers click outbound links and (in some cases) complete a purchase. We don't accept payment in exchange for higher rankings, more prominent placement, or favorable reviews. Read our full disclosure policy if you want the audit-grade detail.
Are your reviewers actually medical professionals?+
Yes. Every clinical claim is reviewed by board-certified physicians or clinicians with verifiable credentials (ABMS certification, state license, NPI). See our editorial board page — each reviewer has a public profile with credentials you can independently verify via free public registries.
Not sure where to start?
Five questions, personalized recommendation. Editorial picks, no paid placement.
